CA2936086C - Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome - Google Patents

Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome Download PDF

Info

Publication number
CA2936086C
CA2936086C CA2936086A CA2936086A CA2936086C CA 2936086 C CA2936086 C CA 2936086C CA 2936086 A CA2936086 A CA 2936086A CA 2936086 A CA2936086 A CA 2936086A CA 2936086 C CA2936086 C CA 2936086C
Authority
CA
Canada
Prior art keywords
composition
athl
patient
dose
intravenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2936086A
Other languages
English (en)
French (fr)
Other versions
CA2936086A1 (en
Inventor
Michael Har-Noy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of CA2936086A1 publication Critical patent/CA2936086A1/en
Application granted granted Critical
Publication of CA2936086C publication Critical patent/CA2936086C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2936086A 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome Active CA2936086C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461924936P 2014-01-08 2014-01-08
US61/924,936 2014-01-08
PCT/US2015/010658 WO2015105999A1 (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Publications (2)

Publication Number Publication Date
CA2936086A1 CA2936086A1 (en) 2015-07-16
CA2936086C true CA2936086C (en) 2024-02-27

Family

ID=53494410

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936086A Active CA2936086C (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Country Status (12)

Country Link
US (3) US10272143B2 (enExample)
EP (1) EP3091990B1 (enExample)
JP (1) JP6557240B2 (enExample)
KR (1) KR102503400B1 (enExample)
CN (1) CN105899219B (enExample)
AU (1) AU2015204770B2 (enExample)
BR (1) BR112016015736B1 (enExample)
CA (1) CA2936086C (enExample)
IL (1) IL246643B (enExample)
PH (1) PH12016501359A1 (enExample)
SG (2) SG10201908048QA (enExample)
WO (1) WO2015105999A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150305983A1 (en) * 2009-11-20 2015-10-29 The University Of Versailles Saint-Quentin-En- Yvelines Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
US20190069528A1 (en) * 2016-03-21 2019-03-07 The George Washington University Engineered human hookworms as a novel biodelivery system for vaccines and biologicals
CN111886249A (zh) * 2017-09-18 2020-11-03 西托戴恩股份有限公司 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法
USD1001795S1 (en) 2019-10-01 2023-10-17 Microsoft Corporation Computing device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
WO2000066141A2 (en) 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
KR20070019635A (ko) * 2003-08-28 2007-02-15 더 임뮨 리스판스 코포레이션 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
OA13246A (en) 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
EP1749090B1 (en) 2004-03-01 2017-05-17 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
US8043619B2 (en) * 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
WO2010051521A1 (en) 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
AU2011240752B2 (en) * 2010-04-13 2016-07-28 Immunovative Therapies, Ltd. Methods and compositions for inhibition of Treg cells
WO2011130247A2 (en) 2010-04-14 2011-10-20 The Penn State Research Foundation Strategies for the transgenic manipulation of filamentous fungi

Also Published As

Publication number Publication date
US10729754B2 (en) 2020-08-04
EP3091990A4 (en) 2017-10-04
IL246643A0 (en) 2016-08-31
AU2015204770A1 (en) 2016-08-18
JP2017502058A (ja) 2017-01-19
WO2015105999A1 (en) 2015-07-16
EP3091990A1 (en) 2016-11-16
BR112016015736A2 (enExample) 2017-08-08
US20180200348A1 (en) 2018-07-19
PH12016501359A1 (en) 2016-08-22
EP3091990B1 (en) 2021-05-12
CA2936086A1 (en) 2015-07-16
CN105899219A (zh) 2016-08-24
AU2015204770B2 (en) 2020-07-02
SG10201908048QA (en) 2019-10-30
US20150190488A1 (en) 2015-07-09
IL246643B (en) 2020-02-27
US20200368334A1 (en) 2020-11-26
US10272143B2 (en) 2019-04-30
KR20160124096A (ko) 2016-10-26
CN105899219B (zh) 2021-08-13
SG11201605440TA (en) 2016-08-30
BR112016015736B1 (pt) 2022-01-04
KR102503400B1 (ko) 2023-02-23
JP6557240B2 (ja) 2019-08-07

Similar Documents

Publication Publication Date Title
Roff et al. The significance of interferon-γ in HIV-1 pathogenesis, therapy, and prophylaxis
Hel et al. HIV infection: first battle decides the war
US20200368334A1 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
Miller et al. Dendritic cell dysregulation during HIV‐1 infection
Mehraj et al. Immune suppression by myeloid cells in HIV infection: new targets for immunotherapy
Berendam et al. Challenges and opportunities of therapies targeting early life immunity for pediatric HIV cure
Poccia et al. Innate T-cell immunity in HIV infections: the role of Vg9Vd2 T lymphocytes
Pantaleo et al. Vaccine and immunotherapeutic interventions
KR20260046169A (ko) Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
Arenas et al. Recent advances in CD8+ T cell-based immune therapies for HIV cure
Wilson et al. Translating insights from persistent LCMV infection into anti-HIV immunity
Van Gulck et al. Role of dendritic cells in HIV-immunotherapy
TWI714529B (zh) 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療
EP4547659A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
Tiemessen et al. Elite controllers: understanding natural suppressive control of HIV-1 infection
KR20230107288A (ko) gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
HK1227297B (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
HK1227297A1 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
Yager Natural and therapy-induced immune control of HIV-1
Lori Virostatics: A new frontier in the treatment of HIV/AIDS
Youle The Future of IL-2 in HIV
Montaner HAART-Mediated Immune Reconstitution as a Target for Therapy Management and Immunotherapy
Weiner Active Vaccine Immune Therapy for HIV-1
Autran Therapeutic Immunization Against HIV
Perno Immunological Effects of Novel Mutational Strategies for Viral Escape

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200103

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219